scholarly journals Evaluation of HBsAg Quantification as Surrogate to HBV DNA Viral Load in Hepatitis B Infected Patients in Anambra State, Nigeria

2020 ◽  
Vol 10 (03) ◽  
pp. 129-140
Author(s):  
Chinwe Obiomah ◽  
Grace Amilo ◽  
Israel Ndulue
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Anambra State

scholarly journals Relationship between HBV-DNA viral load and transaminase enzymes in hepatitis B patients in a low setting area

2021 ◽  
Vol 25 (1) ◽  
pp. S226-S226
Author(s):  
Arum Tri WAHYUNINGSIH ◽  
Osman SIANIPAR ◽  
Adika Zhulhi ARJANA ◽  
Rhaina KHAIRANI ◽  
Budi MULYONO
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Hbv Dna

scholarly journals Decreased levels of serum zonulin and copeptin in chronic Hepatitis-B patients

2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Mustafa Kerem Calgin ◽  
Yeliz Cetinkol
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Normal Population ◽  
Antiviral Treatment ◽  
Inverse Correlation ◽  
Systemic Circulation ◽  
Hbv Dna ◽  
Significant Difference

Background & Objective: Liver and intestines are anatomically and physiologically linked. Zonulin is a protein modulating intercellular tight junctions and regulating intestinal permeability. Copeptin was studied as a marker of systemic circulation disorders in research about vasopressin and was associated with liver disease prognosis. Serum zonulin and copeptin levels were measured in patients with diagnosis of chronic hepatitis B (CHB) with the aim of easing antiviral treatment management in clinical applications and to investigate the association with normal population and viral load. Methods: Analysis included the serum of 30 CHB patients and 17 controls. HBV-DNA real-time PCR tests were completed. CHB patients were divided into three subgroups according to viral load in serum. Zonulin and copeptin levels were measured using ELISA kits. Results: Serum zonulin and copeptin levels were significantly low in CHB patients compared to controls (p<0.001). When CHB subgroups are investigated in terms of serum zonulin and copeptin levels, there was an inverse correlation observed with significant difference (p<0.01, p<0.05). Conclusion: The negative correlation between serum zonulin and copeptin with HBV-DNA load revealed in our study shows they may be used to monitor treatment. Zonulin and copeptin assays provide the possibility of developing new approaches to CHB diagnosis and monitoring. doi: https://doi.org/10.12669/pjms.35.3.144 How to cite this:Calgin MK, Cetinkol Y. Decreased levels of serum zonulin and copeptin in chronic Hepatitis-B patients. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.144 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Detection of HBV DNA by PCR and its application in clinical transfusion

2018 ◽  
Vol 1 (1) ◽  
pp. 22
Author(s):  
Shunqing Li
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Quantitative Polymerase Chain Reaction ◽  
Hbv Dna ◽  
Serological Markers ◽  
Serologic Test ◽  
Chain Reaction ◽  
Medical Disputes ◽  
B Virus ◽  
Polymerase Chain

<p><strong><em> </em></strong>This study was to detect the hepatitis B virus (HBV) DNA copies in patients through blood transfusions; recessive carriers with HBsAg negative but HBV DNA positive were further studied to see the content and distribution of HBV in patients, and provide evidence for the clinical treatment. A total of 532 blood samples collected from July 2014 to July 2015 were tested for HBV-DNA viral load and hepatitis B serological markers using quantitative Polymerase Chain Reaction (qPCR) and serologic test (five serological markers of hepatitis B). The results showed that, 3 cases were HBV serology negative and the HBV-DNA viral load was in the range of 250-500 whereas only 1 case was HBsAb positive and the HBV-DNA viral load was above 500. qPCR, for detecting HBV DNA, together with serological routine test can effectively reduce HBV infection during transfusion and prevent medical disputes.</p>

Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA =9 Log10 Copies/Ml)

2012 ◽  
Vol 142 (5) ◽  
pp. S-954
Author(s):  
Stuart C. Gordon ◽  
Patrick Marcellin ◽  
Zahary Krastev ◽  
Andrzej Horban ◽  
Jörg Petersen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tenofovir Disoproxil Fumarate ◽  
High Viral Load ◽  
Hbv Dna

scholarly journals HBeAg Status among Chronic Hepatitis B Patients at A Referral Hospital of Bangladesh

2017 ◽  
Vol 6 (2) ◽  
pp. 60-63
Author(s):  
Farjana Majid ◽  
Ahmed Lutful Moben ◽  
Dilroze Hussain ◽  
Md Faiz Ahmad Khondaker
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Cross Sectional Study ◽  
Hbv Dna ◽  
Cross Sectional ◽  
Total Study Population ◽  
The Status ◽  
Hbeag Status

Background: HBeAg status in chronic hepatitis B patients is important for outcome and treatmentObjective: The purpose of the present study was to see the status of HBeAg Chronic Hepatitis B (CHB) patients.Methodology: This cross sectional study was conducted in the Department of Virology at Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka between July 2010 to June 2011. Serologically diagnosed CHB patients were enrolled for the study. The HBV DNA was quantified. Samples were tested for HBeAg with ELISA kit.Results: A total of 200 serologically diagnosed CHB patients were enrolled for the study. Among the total study population, HBeAg positive CHB patients were 74(37%) cases and HBeAg negative patients were 126 (63%) cases. Among the HBeAg negative patients, viral load was less and patients were significantly older. The mean viral load of HBeAg positive and HBeAg negative was 64012042 and 2.83i2.55 respectively. HBV DNA was a more reliable indicator of the presence of virus than HBeAg, and was detected in 98.65% (73/74) HBeAg positive carriers, and in 66.67% (84/126) HBeAg negative patients.Conclusion: HBeAg negativity is more prevalent among the CHB patients in Bangladesh.J Shaheed Suhrawardy Med Coll, 2014; 6(2):60-63

scholarly journals Prevalence of hepatitis B virus genotypes among patients with liver disease in Eritrea

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mohammed Elfatih Hamida ◽  
Saud Mohammed Raja ◽  
Yodahi Petros ◽  
Munir Wahab ◽  
Yemane Seyoum ◽  
...  
Keyword(s):  
Viral Load ◽  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Hbv Dna ◽  
Hbv Genotype ◽  
Hbv Genotypes ◽  
B Virus ◽  
Intermediate Endemicity

AbstractEritrea is an East African multiethnic country with an intermediate endemicity for hepatitis B. Our aim was to establish the most prevalent genotypes of hepatitis B virus (HBV) among patients with liver disease. A total of 293 Eritrean patients with liver disease who were hepatitis B surface antigen (HBsAg) positive were enrolled. All sera were tested for liver transaminases, HBV DNA viral load, and hepatitis B seromarkers including HBsAg, anti-HBcAb (total), HBeAg, and anti-HBeAb. Those reactive for HBsAg and anti-HBc (total) were further tested for HBV genotyping. The median (interquartile range) of HBV DNA viral load and ALT levels were 3.47 (1.66) log IU/mL and 28 (15.3) IU/L, respectively. Using type-specific primer-based genotyping method, 122/293 (41.6%) could be genotyped. Irrespective of mode of occurrence, HBV genotype D (21.3%) was the predominant circulating genotype, followed by genotypes C (17.2%), E (15.6%), C/D (13.1%), and C/E (10.7%). Genotypes C/D/E (7.4%), A/D (4.9%), D/E (4.1%), A (2.5%), and B, A/E, B/E, and A/D/C (0.8%) were also present. HBV in Eritrea is comprised of a mixture of HBV genotypes. This is the first study of HBV genotyping among patients with liver disease in Eritrea.

scholarly journals Two-year Single-Center Real-Life Data of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B Patients in Togo

2021 ◽  
pp. 52
Author(s):  
◽  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Teaching Hospital ◽  
Tenofovir Disoproxil Fumarate ◽  
Clinical Signs ◽  
Real Life ◽  
Hbv Dna ◽  
Complete Suppression

Objective: to evaluate the treatment efficacy of Tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) in the Teaching hospital campus of Lome. Patients and method: retrospective cross-sectional study, conducted in the outpatient department of the Hepato-Gastro-Enterology department of the Teaching hospital campus of Lome from January 2018 and December 2020. Patients with HBsAg were included. Outpatient patients having achieved at least HBeAg, anti-HBe antibody, anti-HCV antibody, anti-HBc IgG; viral load hepatic assessment; retroviral serology. Some patients had achieved actitest-fibrotest. Patients with abdominal pain, clinical signs of portal hypertension or hepatocellular insufficiency had achieved alphafetoprotein, protidogram, and abdominal ultrasound. These explorations made it possible to classify patients into different virological profiles. Results: More than sixty-four percent of the patients were male. The patients were asymptomatic at 97.37%. HBeAg was positive in 15.19% of patients. The viral load was detectable in 80.43% of cases with a value of 52000000 IU / ml +/- 280000000UI / ml. Ninety-five point twenty-four patients had an inflammatory activity less than 2 and 52.38% a fibrosis greater than 2 on the Metavir grid. The APRI and Fib-4 scores found a strong predictive value for fibrosis in 16.22% and 11.01% of cases, respectively. HBeAg negative chronic hepatitis was the most common virologic profile (58%). Cirrhosis was the most common complication (9.97%). Tenofovir was the therapeutic molecule used. At 12 months of treatment, HBe seroconversion was noted in 100% of cases, an undetectable viral load in 50% of cases and normalization of the hepatic balance in 84% of cases. No side effects of the treatment were reported Conclusion: TDF treatment shows high rate of complete virologic response in CHB patients. TDF is tolerable and safe during the 96 weeks of treatment period. Monitoring of HBV DNA level and drug adherence is important for achieving complete suppression of HBV DNA, particularly in patients with high viral load.

Sign in / Sign up

Export Citation Format

Share Document